NCT02231775 2026-02-13
Dabrafenib and Trametinib Before and After Surgery in Treating Patients With Stage IIIB-C Melanoma With BRAF V600 Mutation
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
Clinical Trials
30 trialsNCT02910700 2025-12-17
Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT01972347 2025-12-16
Neo Combi
Melanoma Institute Australia
Phase 2 Active not recruiting
NCT07092670 2025-09-05
MELAFERT: Impact of Adjuvant Therapy on FERTility in Patients With Resected MELAnoma at High Risk of Relapse.
Intergruppo Melanoma Italiano
Recruiting
NCT05388877 2025-08-19
E6201 and Dabrafenib for the Treatment of Central Nervous System Metastases From BRAF V600 Mutated Metastatic Melanoma
Mayo Clinic
Phase 1 Terminated
NCT03026517 2025-01-23
Clinical Trial of Phenformin in Combination With BRAF Inhibitor + MEK Inhibitor for Patients With BRAF-mutated Melanoma
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT02872259 2025-01-14
BGB324 in Combination With Pembrolizumab or Dabrafenib/Trametinib in Metastatic Melanoma
Haukeland University Hospital
Phase 1/2 Completed
NCT02392871 2024-11-27
CombiRT
Melanoma and Skin Cancer Trials Limited
Phase 1/2 Completed
NCT04310397 2024-10-30
Dabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage IIIB/C/D Melanoma
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT02143050 2023-11-18
Study of Dabrafenib, Trametinib and Metformin for Melanoma Patients
University of Louisville
Phase 1/2 Withdrawn
NCT04059224 2023-09-26
TraMel-WT
Universitair Ziekenhuis Brussel
Phase 2 Completed
NCT03272464 2023-09-22
INCB039110 in Combination With Dabrafenib and Trametinib in Patients With BRAF-mutant Melanoma and Other Solid Tumors.
Massachusetts General Hospital
Phase 1 Terminated
NCT05299580 2023-09-14
"Dabrafenib and Trametinib in Circulating Free DNA BRAFV600 Mutated Metastatic Melanoma Patients: a Prospective Phase II, Open Label, Multicentre Study - (Bioliquid TAILOR Study - BIOTAILOR)"
Fondazione Melanoma Onlus
Phase 2 Withdrawn
NCT02858921 2023-08-30
Neo Trio
Melanoma Institute Australia
Phase 2 Unknown
NCT03563729 2023-07-13
MEMBRAINS
Herlev Hospital
Phase 2 Recruiting
NCT02052193 2022-12-19
Evaluation of Photosensitivity in Dabrafenib or Vemurafenib Treated Metastatic Melanoma Patients - a Phase IIa/IIb Study
University Hospital Tuebingen
Phase 2 Terminated
NCT05171374 2022-06-01
RATIONALE
MelanomaPRO, Russia
Unknown
NCT03754179 2021-04-28
COMBI-R2
Universitair Ziekenhuis Brussel
Phase 1/2 Unknown
NCT03352947 2020-12-08
INTERIM
Cambridge University Hospitals NHS Foundation Trust
Phase 2 Completed
NCT03972046 2020-10-19
Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma
TriHealth Inc.
Phase 2 Withdrawn
NCT02410863 2020-10-14
BOTTOM
University Hospital, Essen
Phase 2 Terminated
NCT03088176 2020-10-12
Combining Talimogene Laherparepvec With BRAF and MEK Inhibitors in BRAF Mutated Advanced Melanoma
West Cancer Center
Phase 1 Unknown
NCT01682213 2020-05-26
Adjuvant Dabrafenib (GSK2118436) in Patients With Surgically Resected AJCC Stage IIIC Melanoma Characterized by a BRAFV600E/K Mutation
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT02296996 2019-01-23
Dabrafenib and Trametinib for BRAF-inhibitor Pretreated Patients
Universitair Ziekenhuis Brussel
Phase 2 Completed
NCT02915666 2018-05-15
A Clinical Trial of Patients With Melanoma
University of Texas Southwestern Medical Center
Phase 1 Withdrawn
NCT01721603 2018-01-23
Dabrafenib and Trametinib With Radiosurgery in Melanoma Brain Mets
University of California, San Francisco
Phase 2 Terminated
NCT02625337 2017-09-15
IMPemBra
The Netherlands Cancer Institute
Phase 2 Unknown
NCT01701037 2017-06-23
Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By Surgery
Vanderbilt-Ingram Cancer Center
Phase 2 Terminated
NCT01619774 2016-12-12
An Open-Label Phase II Study of the Combination of GSK2118436 and GSK1120212 in Patients With Metastatic Melanoma Which is Refractory or Resistant to BRAF Inhibitor
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02357732 2015-12-11
Study of the Anti-PD-1 Antibody Nivolumab in Combination With Dabrafenib and/or Trametinib
University of Pittsburgh
Phase 1 Withdrawn